Burnout is not an individual failure: it’s a systems imbalance, biologically and organizationally, write Tony Martignetti and ...

On this week's episode of the Business of Biotech, Bruce Culleton, M.D., CEO at ProKidney, talks about moving from academic research to industry and the role a key mentor played in his career path.

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

Spinning off a $4 billion biopharma business is no easy task. Integrated functions need to be separated, governance boards created, leadership teams assembled, and corporate headquarters established.

When working groups at AbbVie first began evaluating the use of digital technologies in clinical trials, the discussions were mostly conceptual. Individuals agonized over the right approach, the ...

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

Essential medicines play a vital role in America’s health, and the supply is closely monitored by the FDA and industry groups. These medicines sustain life, provide life support and/or the prevention ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...

In a complex global and competitive world, formulating a plan without testing it against likely external reactions is the equivalent of walking into a battlefield without the right weapons or a plan ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

The cyber security situation for nearly every industry is a precarious one, but few have it worse right now than biotech and pharma. I see this first hand in the day to day work my company does ...

Vivani’s subdermal implant NanoPortal device, a platform drug delivery technology, is designed to deliver a near-constant and minimally fluctuating dose of an active pharmaceutical drug for a duration ...